Relative Risk of HIV Transmission by Risk Factor Among ELISA Positive Infants.

4<p>N = 65– “don’t know” and “missing” responses are not presented in the table.</p>5<p>Caregiver report prior to ELISA testing.</p

Self-Reported Participation in PMTCT Activities among HIV-infected Mothers.

1<p>Caregiver report prior to ELISA testing.</p

Transmission Rates Overall and by District.

<p>Transmission Rates Overall and by District.</p

HIV Treatment Regimen During Labor.

3<p>Any of the first or second line regimens used in Malawi at the time, including: D4T+3TC+NVP, d4T+3TC/EFV, AZT+3TC/EFV, AZT+3TC/TDF/LPV/r.</p

Additional file 1 of Age-disparate and intergenerational sex partnerships and HIV: the role of gender norms among adolescent girls and young women in Malawi

Supplementary Material

Primers used in the optimized in-house assay.

<p>*: PRTM-F1 is a mixture of primers F1a and F1b at a ratio of 1:1 (w/w).</p

Difference of mixture chromatographs generated independently by 3 different operators using the optimized in-house assay from one PT sample.

<p>Panel A shows 2 codons (37 and 41 of RT) with nucleotide base calling of AYR; Panel B shows the AWR at codon 41 (the second peaks at codon 37 were not detected in this replicate); Panel C shows ACR at codon 37 (minor T was not called by the ReCall at the cutoff of 15%) and AHR at codon 41 (almost equal height of second and third peak at the 2^nd position).</p

Summary of samples used in the study, including plasma and dried blood spots (DBS).

a<p>HIV negative specimens collected from pregnant women in Tanzania used for assay specificity analysis; ^b Plasma-matched DBS samples collected from voluntary counseling and testing (VCT) sites in Ho Chi Minh City enrolled in an HIV-1 threshold survey; ^cPlasma-matched DBS samples collected from patients enrolled in the Nigeria HIVDR perspective monitoring survey at 12-15 months after commencement of first line antiretroviral therapy; ^d Not available.</p

Pairwise sequence identity analysis between the optimized in-house and TRUGENE® assays.

<p>Pairwise sequence identity analysis between the optimized in-house and TRUGENE® assays.</p

Genotyping efficiency and drug resistance-associated mutations identified in protease (PR) and reverse transcriptase (RT) by the optimized in-house assay from dried blood spots (DBS) PT panels.

<p>*N/A:not available; bold and underlined residues were partially discordant resistance mutations from paired DBS shipped under different temperature conditions.</p